Desmopressin vs C-peptide
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and C-peptide (Connecting peptide (C-peptide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | C-peptide |
|---|---|---|
| Category | Cognitive Enhancement | Pain Management |
| Full Name | 1-Deamino-8-D-arginine vasopressin | Connecting peptide (C-peptide) |
| Molecular Weight | 1069.22 Da | 3020.3 Da |
| Half-Life | 1.5-3 hours | ~20-30 min |
| Amino Acids | 9 | 31 |
| Typical Dose | 10-40 mcg intranasal | no approved analgesic dose|research-only |
| Route | Intranasal/Oral | IV|subQ |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 46 |
| Research Status | Clinical | Pre-clinical |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.